Your AI-Trained Oncology Knowledge Connection!
Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.
Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.
Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the differences between immunotherapy and chemotherapy.
Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.
Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.
Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.
Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.
Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses considering factors when selecting an immunotherapy agent for a patient with melanoma.
Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.
Steven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.
Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.
Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.
Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the most important factors of bilateral salpingo-oophorectomy (BSO) to convey to patients with ovarian cancer.
Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.
Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ.
Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.
Robert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.
Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.
Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the current treatment approaches being evaluated for patients with anaplastic thyroid cancer.
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.
Constantine S. Tam, MD, Consultant Hematologist, Division of Hematology and Oncology, Peter MacCallum Cancer Center, Melbourne, Australia discusses BCL2 inhibitors in chronic lymphocytic leukemia (CLL).
Lowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors.
Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.
Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).
James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).
Philip McCarthy, BA, MD, professor of oncology and internal medicine director, blood and marrow transplant program, Roswell Park Cancer Institute discusses maintenance therapy for multiple myeloma patients that are eligible for transplant.
